1.Sutton ALM, Harper LM, Tita ATN. Hypertensive Disorders in Pregnancy. Obstetrics and gynecology clinics of North America. 2018;45(2):333–47. Epub 2018/05/12.
2.Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. Journal of obstetrics and gynaecology Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. 2014;36(7):575–6. Epub 2014/09/04.
3.von Dadelszen P, Magee LA. Pre-eclampsia: an update. Current hypertension reports. 2014;16(8):454. Epub 2014/06/12.
4.Feyereisen E, Mendez Lozano DH, Taieb J, Hesters L, Frydman R, Fanchin R. Anti-Mullerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006;12(6):695–703. Epub 2006/06/24.
5.de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility and sterility. 2002;77(2):357–62. Epub 2002/02/01.
6.van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertility and sterility. 2005;83(4):979–87. Epub 2005/04/12.
7.Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009;63(4):280–91. Epub 2009/07/28.
8.Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-mullerian hormone. J Clin Endocrinol Metab. 2013;98(2):729–35. Epub 2013/01/15.
9.de Kat AC, Verschuren WM, Eijkemans MJ, van der Schouw YT, Broekmans FJ. The association of low ovarian reserve with cardiovascular disease risk: a cross-sectional population-based study. Human reproduction (Oxford, England). 2016;31(8):1866–74. Epub 2016/08/09.
10.Tehrani FR, Erfani H, Cheraghi L, Tohidi M, Azizi F. Lipid profiles and ovarian reserve status: a longitudinal study. Human reproduction (Oxford, England). 2014;29(11):2522–9. Epub 2014/10/01.
11.de Kat AC, Broekmans FJ, Laven JS, van der Schouw YT. Anti-Mullerian Hormone as a marker of ovarian reserve in relation to cardio-metabolic health: a narrative review. Maturitas. 2015;80(3):251–7. Epub 2015/02/03.
12.de Kat AC, Verschuren WM, Eijkemans MJ, Broekmans FJ, van der Schouw YT. Anti-Mullerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women: Results From the Doetinchem Cohort Study. Circulation. 2017;135(6):556–65. Epub 2017/02/06.
13.Kim C, Pan Y, Braffett BH, Arends VL, Steffes MW, Wessells H, et al. Anti-Mullerian hormone and its relationships with subclinical cardiovascular disease and renal disease in a longitudinal cohort study of women with type 1 diabetes. Women’s midlife health. 2017;3:5. Epub 2017/08/18.
14.Yarde F, Maas AH, Franx A, Eijkemans MJ, Drost JT, van Rijn BB, et al. Serum AMH levels in women with a history of preeclampsia suggest a role for vascular factors in ovarian aging. J Clin Endocrinol Metab. 2014;99(2):579–86. Epub 2013/11/20.
15.Shand AW, Whitton K, Pasfield A, Nassar N, McShane M, Han X, et al. Evaluation of anti-Mullerian hormone in the first trimester as a predictor for hypertensive disorders of pregnancy and other adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol. 2014;54(3):244–9. Epub 2014/03/05.
16.Tokmak A, Guney G, Aksoy RT, Guzel AI, Topcu HO, Kececioglu TS, et al. May maternal anti-mullerian hormone levels predict adverse maternal and perinatal outcomes in preeclampsia? The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2015;28(12):1451–6. Epub 2014/08/19.
17.Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002;47(6):408–26. Epub 2003/03/20.
18.Diehl CL, Brost BC, Hogan MC, Elesber AA, Offord KP, Turner ST, et al. Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. American journal of obstetrics and gynecology. 2008;198(5):e11–3. Epub 2008/02/05.
19.Klemmensen AK, Olsen SF, Osterdal ML, Tabor A. Validity of preeclampsia-related diagnoses recorded in a national hospital registry and in a postpartum interview of the women. American journal of epidemiology. 2007;166(2):117–24. Epub 2007/06/09.
20.Altman DG, Chitty LS. Charts of fetal size: 1. Methodology. Br J Obstet Gynaecol. 1994;101(1):29–34. Epub 1994/01/01.
21.Royston P, Wright EM. How to construct ‘normal ranges’ for fetal variables. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 1998;11(1):30–8. Epub 1998/03/25.
22.Royston P, Wright EM. Goodness-of-fit statistics for age-specific reference intervals. Stat Med. 2000;19(21):2943–62. Epub 2000/10/24.
23.Tehrani FR, Mansournia MA, Solaymani-Dodaran M, Azizi F. Age-specific serum anti-Mullerian hormone levels: estimates from a large population-based sample. Climacteric. 2014;17(5):591–7. Epub 2014/04/11.
24.D’Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Statistics in medicine. 1990;9(12):1501–15.
25.Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143(3):1076–84. Epub 2002/02/28.
26.Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142(11):4891–9. Epub 2001/10/19.
27.Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006;21(9):2223–7. Epub 2006/05/25.
28.Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction (Cambridge, England). 2006;131(1):1–9. Epub 2006/01/03.
29.Anderson EL, Fraser A, McNally W, Sattar N, Lashen H, Fleming R, et al. Anti-mullerian hormone is not associated with cardiometabolic risk factors in adolescent females. PloS one. 2013;8(5):e64510. Epub 2013/06/14.
30.Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause (New York, NY). 2006;13(2):265–79. Epub 2006/04/29.
31.van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347(9003):714–8. Epub 1996/03/16.
32.Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, et al. Age at natural menopause and risk of cardiovascular disease. Archives of internal medicine. 1999;159(10):1061–6. Epub 1999/05/21.
33.Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. The New England journal of medicine. 1998;338(23):1650–6. Epub 1998/06/06.
34.Chu MC, Rath KM, Huie J, Taylor HS. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum Reprod. 2003;18(8):1570–3. Epub 2003/07/23.
35.Koninger A, Kauth A, Schmidt B, Schmidt M, Yerlikaya G, Kasimir-Bauer S, et al. Anti-Mullerian-hormone levels during pregnancy and postpartum. Reprod Biol Endocrinol. 2013;11:60. Epub 2013/07/13.
36.Koninger A, Schmidt B, Mach P, Damaske D, Niessen S, Kimmig R, et al. Anti-Mullerian-Hormone during pregnancy and peripartum using the new Beckman Coulter AMH Gen II Assay. Reprod Biol Endocrinol. 2015;13:86. Epub 2015/08/08.
37.Ramezani Tehrani F, Mansournia MA, Solaymani-Dodaran M, Steyerberg E, Azizi F. Flexible parametric survival models built on age-specific antimullerian hormone percentiles are better predictors of menopause. Menopause. 2016;23(6):676–81. Epub 2016/03/30.
38.Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC. Maternal serum anti-Mullerian hormone at 11–13 weeks’ gestation in the prediction of preeclampsia. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2015;28(8):865–8. Epub 2014/06/24.